Richard Bungay has been appointed as the new chief financial officer (CFO) at 4basebio, replacing David Roth, who stepped down from the board earlier this year.

Bungay joins the synthetic DNA manufacturer with over 30 years of senior finance and strategic execution experience within the pharmaceutical and biotechnology sectors.

His last role as at the UK-based private biotech firm, Sitala Bio, where he helped lead a strategic repositioning of the business, working closely with the chief executive officer (CEO) and board to rase a Series A round and execute an in-licensing deal with Fosun Pharma for up to $670m.

He has also worked across CEO and CFO roles at a number of biopharma firms.

CEO at 4basebio, Dr Amy Walker, said: "Richard has had a long and accomplished career in the industry, bringing significant experience with high growth public and private companies; we are thrilled that he has decided to join 4basebio. 4basebio is transitioning into a phase of accelerated commercial growth, and his strategic and financial expertise will be invaluable to support us on this journey.

"Richard’s appointment completes the build out of the senior leadership team to help us scale our operations to meet the growing need for high quality synthetic DNA products for advanced therapies and personalised medicines."

Bungay concluded: "I’ve been following 4basebio’s progress for several years and have been impressed by what the team has achieved in such a short time. I look forward to working with Amy and the wider team to support the company’s continued growth and help realise the growth potential of this exciting business as it seeks to establish a leadership position in the manufacturing of next-generation therapeutics."

---